Meeting Report
Bing Cui, Patrick A. Eyers, Leonard L. Dobens, Nguan Soon Tan, Peter D. Mace, Wolfgang A. Link, Endre Kiss-Toth, Karen Keeshan, Takuro Nakamura, Warren S. Pear, Yodit Feseha, Jessica Johnston, Arkatiz Carracedo, Marcel Scheideler, Zabran llyas, Robert C. Bauer, Jorge D. Erusalimsky, Dominika Grzesik, Juan Salamanca-Viloria, Xiaoxi Lv, Yishi Jin, Ke Li, Guillermo Velasco, Shuang Shang, Jose M. Lizcano, Xiaowei Zhang, Jichao Zhou, Jiaojiao Yu, Fang Hua, Feng Wang, Shanshan Liu, Jinmei Yu, Zhuowei Hu. Highlights of the 2nd International Symposium on Tribbles and Diseases: tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer[J]. Acta Pharmaceutica Sinica B, 2019, 9(2): 443-454

Highlights of the 2nd International Symposium on Tribbles and Diseases: tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer
Bing Cuia, Patrick A. Eyersb, Leonard L. Dobensc, Nguan Soon Tand,e,f,g, Peter D. Maceh, Wolfgang A. LinkI,j,k, Endre Kiss-Tothl, Karen Keeshanm, Takuro Nakamuran, Warren S. Pearo, Yodit Fesehap,q, Jessica Johnstonl, Arkatiz Carracedor,s,t,u, Marcel Scheidelerv,w,x,y, Zabran llyasl, Robert C. Bauerz, Jorge D. Erusalimskyaa, Dominika Grzesikab, Juan Salamanca-Viloriaac,ad, Xiaoxi Lva, Yishi Jinae, Ke Lia,af, Guillermo Velascoag, Shuang Shanga, Jose M. Lizcanoah, Xiaowei Zhanga, Jichao Zhoua, Jiaojiao Yua, Fang Huaa, Feng Wanga, Shanshan Liua, Jinmei Yua, Zhuowei Hua
a State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
b Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK;
c Division of Molecular Biology and Biochemistry, School of Biological Sciences, University of Missouri-Kansas City, Kansas City, MO 64110, USA;
d School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore;
e Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 639798, Singapore;
f Institute of Molecular and Cell Biology, Singapore 138673, Singapore;
g KK Women's and Children Hospital, Singapore 229899, Singapore;
h Biochemistry Department, School of Biomedical Sciences, University of Otago, Dunedin 9054, New Zealand;
i Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas, Faro 8005-139, Portugal;
j Department of Biomedical Sciences and Medicine, University of Algarve, Faro 8005-139, Portugal;
k Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro 8005-139, Portugal;
l Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield S10 2RX, UK;
m Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland G61 1QH, UK;
n Division of Carcinogenesis, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan;
o Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA;
p Centre de Recherche en Transplantation et Immunologie (ou CRTI), Inserm, Université de Nantes, Nantes, France, CHU Nantes, Nantes, France;
q Institut de Transplantation Urologie Néphrologie (ou ITUN), CHU Nantes, Nantes, France;
r CIC bioGUNE, Bizkaia 48160, Spain;
s CIBERONC, Madrid 28029, Spain;
t Ikerbasque, Basque Foundation for Science, Bilbao 48080, Spain;
u Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), Bilbao 48080, Spain;
v Institute for Diabetes and Cancer IDC, Helmholtz Center Munich, Neuherberg 85764, Germany;
w Joint Heidelberg-IDC Translational Diabetes Program, University Hospital Heidelberg, Heidelberg 85764, Germany;
x Molecular Metabolic Control, Medical Faculty, Technical University Munich, Munich 85764, Germany;
y German Center for Diabetes Research (DZD), Neuherberg 85764, Germany;
z Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA;
aa School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff CF5 2YB, UK;
ab Centre for Endocrinology, William Harvey Research Institute, John Vane Science Centre, Queen Mary, University of London, London EC1M 6BQ, UK;
ac Intelligent Pharma-Mind the Byte S. L., Barcelona 08028, Spain;
ad Facultat de Farmàcia, Universitat de Barcelona, Barcelona 08028, Spain;
ae Section of Neurobiology, Division of Biological Sciences, University of California San Diego, La Jolla, CA 92093, USA;
af Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China;
ag Department of Biochemistry and Molecular Biolgy, School of Biology, Complutense University and Instituto de Investigaciones;
Sanitarias San Carlos (IdISSC), Madrid 28040, Spain;
ah Department of Biochemistry and Molecular Biology, Institute of Neurosciences, Faculty of Medicine, Universitat Autonoma de Barcelona, Bellaterra 08193, Spain
Abstract:
The Tribbles (TRIB) family of pseudokinase proteins has been shown to play key roles in cell cycle, metabolic diseases, chronic inflammatory disease, and cancer development. A better understanding of the mechanisms of TRIB pseudokinases could provide new insights for disease development and help promote TRIB proteins as novel therapeutic targets for drug discovery. At the 2nd International Symposium on Tribbles and Diseases held on May 7-9, 2018 in Beijing, China, a group of leading Tribbles scientists reported their findings and ongoing studies about the effects of the different TRIB proteins in the areas of immunity, metabolism, fundamental cell biology and cancer. Here, we summarize important and insightful overviews from 4 keynote lectures, 13 plenary lectures and 8 short talks that took place during this meeting. These findings may offer new insights for the understanding of the roles of TRIB pseudokinases in the development of various diseases.
Key words:    Tribbles    Immunology    Metabolism    Cell biology    Kinase inhibitor    Tumorigenesis    Metastasis    TRIB1    TRIB2    TRIB3    Pseudokinase    Inflammation    Atomic structure    Protein quality control    Ubiqutin   
Received: 2018-07-12     Revised: 2018-11-19
DOI: 10.1016/j.apsb.2018.12.007
Funds: Dr.Zhuowei Hu's work was supported by National Key R&D Program of China (Grant No.2017YFA0205400,China),the National Natural Science Foundation of China (Grant Nos.81530093 and 81773781,China),Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (Grant No.2016-I2M-1-007,China) and CAMS Central Public-interest Scientific Institution Basic Research Fund (Grant No.2017PT3104,China);Dr.Bing Cui's work was supported by grants of the National Natural Science Foundation of China (Grant No.81874316,China),the CAMS Innovation Fund for Medical Sciences (Grant No.2016-I2M-3-008,China);Dr.Patrick A.Eyers's work was supported by grants of from the BBSRC and NWCR (Grant Nos.1088 and 1097,UK);Dr.Leonard L.Dobens's work was supported by grants of NSF (Grant No.IOS-1456023,USA),NIH (Grant No.NIH R21 CA197317,USA);Dr.Nguan Soon Tan's work was supported by grants of Ministry of Education,Singapore (Grant Nos.MOE2014-T2-1-012 and 2012-T1-001-036,Singapore);Dr.Peter D.Mace's work was supported by grants from the Health Research Council of New Zealand,and additionally supported by a Rutherford Discovery Fellowship from the New Zealand government administered by the Royal Society of New Zealand;Dr.Wolfgang Link's work was supported by Fundação para a Ciência e a Tecnologia (FCT) Research Center Grant UID/BIM/04773/2013 Centre for Biomedical Research 1334,by a research grant from Liga Portuguesa Contra o Cancro-Núcleo Regional do Sul (LPCC/NRS,Portugal),Terry Fox,by a FCT 2014 research grant SFRH/BPD/100434/2014 and a ProRegem grant PD/BD/114258/2016(Portugal);Dr.Endre Kiss-Toth's work was supported by European Marie Sklodowska Curie ITN Project TRAIN-TRIBBLES Research and Innovation Network (Grant No.721532,EU) and Innovation Network and the British Heart Foundation (PG/16/44/32146,UK);Dr.Karen Keeshan's work was supported by grants from The Howat Foundation Ltd.(UK),Children with Cancer UK,Bloodwise and the Friends of Paul O'Gorman (UK);Dr.Takuro Nakamura's work was supported by grants of P-CREATE from Japan Agency for Medical Research and Development;Dr.Warren S.Pear's work was supported by grants from the NIH (NIAID,USA),Alex's Lemonade Stand Foundation (USA) and the Samuel Waxman Cancer Research Foundation (USA);Yodit Feseha is supported by European Marie Sklodowska Curie ITN Project TRAIN-TRIBBLES Research and Innovation Network (Grant No.721532,EU).Yodit Feseha's work is conducted in the context of the "Fondation Centaure" (RTRS),which supports a French transplantation research network,the IHU-Cesti project,the DHU Oncogreffe and the LabEX IGO thanks to French government financial support managed by the National Research Agency via the "Investment into the Future" program (Grant Nos.ANR-10-IBHU-005 and ANR-11-LABX-0016-01,France).The IHU-Cesti project is also supported by Nantes Métropole and Région Pays de la Loire (France);Dr.Jessica Johnston's work was supported by grants of the British Heart Foundation (PG/16/44/32146,UK);Dr.Arkatiz Carracedo's work was supported by European Marie Sklodowska Curie ITN Project TRAIN-TRIBBLES Research and Innovation Network (Grant No.721532,EU);Dr.Marcel Scheideler's work was supported by European Marie Sklodowska Curie ITN Project TRAIN-TRIBBLES Research and Innovation Network (Grant No.721532,EU);Dr.Zabran llyas's work was supported by a joint Ph.D studentship beween the A*Star Institute and the University of Sheffield (UK);Dr.Robert C.Bauer's work was supported by funding from the National Institutes of Health National Heart,Lung,and Blood Institute (R01HL141745,USA);Dominika Grzesik's work was supported by European Marie Sklodowska Curie ITN Project TRAIN-TRIBBLES Research and Innovation Network (Grant No.721532,EU);Juan Salamanca-Viloria's work was supported by European Marie Sklodowska Curie ITN Project TRAIN-TRIBBLES Research and Innovation Network (Grant No.721532,EU);Dr.Xiaoxi Lv's work was supported by the National Natural Science Foundation of China (Grant No.81503128,China) and CAMS Innovation Fund for Medical Sciences (Grant No.2016-I2M-1-008,China);Dr.Yishi Jin's work was supported by National Institute of Health (NS R01-035546,USA);Dr.Ke Li's work was supported by the National Natural Science Foundation of China (Grant No.81400140,China),and CAMS Innovation Fund for Medical Sciences (Grant No.2016-I2M-1-011,China);Dr.Guillermo Velasco's work was supported by European Marie Sklodowska Curie ITN Project TRAIN-TRIBBLES Research and Innovation Network (Grant No.721532,EU);Dr.Jose M.Lizcano's work was supported by Spanish Ministry of Economy and Competitiveness (MINECO) and Fondo Europeo de desarrollo Regional (FEDER)(Grant No.INNPACTO/IPT-2012-0614-010000,Spain);Dr.Xiaowei Zhang's work was supported by the National Natural Science Foundation of China (Grant Nos.81400286 and 81530093,China),and the CAMS Innovation Fund for Medical Sciences (Grant No.2016-I2M-1-010,China);Dr.Fang Hua's work was supported by the National Natural Science Foundation of China (Grant Nos.81472717 and 81673474,China),Beijing Natural Science Foundation (Grant No.7162133,China),and the CAMS Innovation Fund for Medical Sciences (Grant No.2016-I2M-1-007,China);Dr.Jiaojiao Yu's work was supported by the National Natural Science Foundation of China (Grant No.81703564,China);Dr.Jinmei Yu's work was supported by the National Natural Science Foundation of China (Grant No.81603129,China).In addition,the Meeting Organizing Committee was greatly thankful to PerkinElmer and Innovent Biologics for their generous financial supports,as well as Dr.Zhuowei Hu's laboratory members for their assistance in preparing and organizing the conference.
Corresponding author: Zhuowei Hu     Email:huzhuowei@imm.ac.cn
Author description:
Service
PDF(KB) Free
Print
0
Authors
Bing Cui
Patrick A. Eyers
Leonard L. Dobens
Nguan Soon Tan
Peter D. Mace
Wolfgang A. Link
Endre Kiss-Toth
Karen Keeshan
Takuro Nakamura
Warren S. Pear
Yodit Feseha
Jessica Johnston
Arkatiz Carracedo
Marcel Scheideler
Zabran llyas
Robert C. Bauer
Jorge D. Erusalimsky
Dominika Grzesik
Juan Salamanca-Viloria
Xiaoxi Lv
Yishi Jin
Ke Li
Guillermo Velasco
Shuang Shang
Jose M. Lizcano
Xiaowei Zhang
Jichao Zhou
Jiaojiao Yu
Fang Hua
Feng Wang
Shanshan Liu
Jinmei Yu
Zhuowei Hu

References:
1. Eyers PA, Keeshan K, Kannan N. Tribbles in the 21st century:the evolving roles of tribbles pseudokinases in biology and disease. Trends Cell Biol 2017;27:284-98.
2. Murphy JM, Mace PD, Eyers PA. Live and let die:insights into pseudoenzyme mechanisms from structure. Curr Opin Struct Biol 2017;47:95-104.
3. Sakai S, Miyajima C, Uchida C, Itoh Y, Hayashi H, Inoue Y. Tribblesrelated protein family members as regulators or substrates of the ubiquitin-proteasome system in cancer development. Curr Cancer Drug Targets 2016;16:147-56.
4. Stein SJ, Mack EA, Rome KS, Pear WS. Tribbles in normal and malignant haematopoiesis. Biochem Soc Trans 2015;43:1112-5.
5. Johnston J, Basatvat S, Ilyas Z, Francis S, Kiss-Toth E. Tribbles in inflammation. Biochem Soc Trans 2015;43:1069-74.
6. Liang KL, Rishi L, Keeshan K. Tribbles in acute leukemia. Blood 2013;121:4265-70.
7. Li K, Wang F, Cao WB, Lv XX, Hua F, Cui B, et al. TRIB3 Promotes APL progression through stabilization of the oncoprotein PML-RARα and inhibition of p53-mediated senescence. Cancer Cell 2017;31:697-710.e7.
8. Byrne DP, Foulkes DM, Eyers PA. Pseudokinases:update on their functions and evaluation as new drug targets. Future Med Chem 2017;9:245-65.
9. Carmody R, Keeshan K. The Tribble with APL:a new road to therapy. Cancer Cell 2017;31:612-3.
10. Torrano V, Valcarcel-Jimenez L, Cortazar AR, Liu X, Urosevic J, Castillo-Martin M, et al. The metabolic co-regulator PGC1α suppresses prostate cancer metastasis. Nat Cell Biol 2016;18:645-56.
11. Arruabarrena-Aristorena A, Zabala-Letona A, Carracedo A. Oil for the cancer engine:the cross-talk between oncogenic signaling and polyamine metabolism. Sci Adv 2018;4:eaar2606.
12. Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, et al. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature 2017;547:109-13.
13. Valcarcel-Jimenez L, Gaude E, Torrano V, Frezza C, Carracedo A. Mitochondrial metabolism:yin and yang for tumor progression. Trends Endocrinol Metab 2017;28:748-57.
14. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559-64.
15. Teo Z, Sng MK, Chan JS, Lim MM, Li Y, Li L, et al. Elevation of adenylate energy charge by angiopoietin-like 4 enhances epithelialmesenchymal transition by inducing 14-3-3γ expression. Oncogene 2017;36:6408-19.
16. Zhu P, Goh YY, Chin HF, Kersten S, Tan NS. Angiopoietin-like 4:a decade of research. Biosci Rep 2012;32:211-9.
17. Lichtenstein L, Mattijssen F, de Wit NJ, Georgiadi A, Hooiveld GJ, van der Meer R, et al. Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab 2010;12:580-92.
18. Zhu P, Tan MJ, Huang RL, Tan CK, Chong HC, Pal M, et al. Angiopoietin-like 4 protein elevates the prosurvival intracellular O2- ratio and confers anoikis resistance to tumors. Cancer Cell 2011;19:401-15.
19. Brouard S, Mansfield E, Braud C, Li L, Giral M, Hsieh SC, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A 2007;104:15448-53.
20. Baron D, Ramstein G, Chesneau M, Echasseriau Y, Pallier A, Paul C, et al. A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft. Kidney Int 2015;87:984-95.
21. Danger R, Chesneau M, Paul C, Guérif P, Durand M, Newell KA, et al. A composite score associated with spontaneous operational tolerance in kidney transplant recipients. Kidney Int 2017;91:1473-81.
22. Ashton-Chess J, Giral M, Mengel M, Renaudin K, Foucher Y, Gwinner W, et al. Tribbles-1 as a novel biomarker of chronic antibody-mediated rejection. J Am Soc Nephrol 2008;19:1116-27.
23. Dugast E, Kiss-Toth E, Docherty L, Danger R, Chesneau M, Pichard V, et al. Identification of tribbles-1 as a novel binding partner of Foxp3 in regulatory T cells. J Biol Chem 2013;288:10051-60.
24. Steinl DC, Kaufmann BA. Ultrasound imaging for risk assessment in atherosclerosis. Int J Mol Sci 2015;16:9749-69.
25. Burkhardt R, Toh SA, Lagor WR, Birkeland A, Levin M, Li X, et al. Trib1 is a lipid-and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. J Clin Invest 2010;120:4410-4.
26. Satoh T, Kidoya H, Naito H, Yamamoto M, Takemura N, Nakagawa K, et al. Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages. Nature 2013;495:524-8.
27. Bauer RC, Sasaki M, Cohen DM, Cui J, Smith MA, Yenilmez BO, et al. Tribbles-1 regulates hepatic lipogenesis through posttranscriptional regulation of C/EBPα. J Clin Invest 2015;125:3809-18.
28. Du K, Herzig S, Kulkarni RN, Montminy M. TRB3:a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 2003;300:1574-7.
29. Prudente S, Sesti G, Pandolfi A, Andreozzi F, Consoli A, Trischitta V. The mammalian tribbles homolog TRIB3, glucose homeostasis, and cardiovascular diseases. Endocr Rev 2012;33:526-46.
30. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell 2012;148:1242-57.
31. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013;45:1274-83.
32. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-13.
33. Wang G, Franklin R, Hong Y, Erusalimsky JD. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol 2005;146:324-32.
34. Hong Y, Wang G, del Arroyo AG, Hernandez J, Skene C, Erusalimsky JD. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation:selectivity of anagrelide for the megakaryocytic lineage. Leukemia 2006;20:1117-22.
35. Ahluwalia M, Donovan H, Singh N, Butcher L, Erusalimsky JD. Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction. J Thromb Haemost 2010;8:2252-61.
36. Ahluwalia M, Butcher L, Donovan H, Killick-Cole C, Jones PM, Erusalimsky JD. The gene expression signature of anagrelide provides an insight into its mechanism of action and uncovers new regulators of megakaryopoiesis. J Thromb Haemost 2015;13:1103-12.
37. Butcher L, Ahluwalia M, Örd T, Johnston J, Morris RH, Kiss-Toth E, et al. Evidence for a role of TRIB3 in the regulation of megakaryocytopoiesis. Sci Rep 2017;7:6684.
38. Murphy JM, Nakatani Y, Jamieson SA, Dai W, Lucet IS, Mace PD. Molecular mechanism of CCAAT-enhancer binding protein recruitment by the TRIB1 pseudokinase. Structure 2015;23:2111-21.
39. Jamieson SA, Ruan Z, Burgess AE, Curry JR, McMillan HD, Brewster JL, et al. Substrate binding allosterically relieves autoinhibition of the pseudokinase TRIB1. Sci Signal 2018;11:eaau0597.
40. O'Connor C, Yalla K, Salomé M, Moka HA, Castañeda EG, Eyers PA, et al. Trib2 expression in granulocyte-monocyte progenitors drives a highly drug resistant acute myeloid leukaemia linked to elevated Bcl2. Oncotarget 2018;9:14977-92.
41. Liang KL, Paredes R, Carmody R, Eyers RA, Meyer S, McCarthy TV, et al. Human TRIB2 oscillates during the cell cycle and promotes ubiquitination and degradation of CDC25C. Int J Mol Sci 2016;17:1378.
42. Rheault TR, Caferro TR, Dickerson SH, Donaldson KH, Gaul MD, Goetz AS, et al. Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors. Bioorg Med Chem Lett 2009;19:817-20.
43. Foulkes DM, Byrne DP, Yeung W, Shrestha S, Bailey FP, Ferries S, et al. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. Sci Signal 2018;11:eaat7951.
44. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing:progress, challenges and recommendations. Nat Rev Drug Discov 2018 Available from:
Similar articles:
1.Bing Cui, Xuetao Cao, Weiping Zou, Yonghong Wan, Ning Wang, Yaohe Wang, Pingping Li, Fang Hua, Yuying Liu, Xiaowei Zhang, Ke Li, Xiaoxi Lv, Bo Huang, Zhuowei Hu.Regulation of immune-related diseases by multiple factors:a meeting report of 2017 International Workshop of the Chinese Academy of Medical Sciences Initiative for Innovative Medicine on Tumor Immunology[J]. Acta Pharmaceutica Sinica B, 2017,7(4): 532-540
2.Hong Lu.Crosstalk of HNF4α with extracellular and intracellular signaling pathways in the regulation of hepatic metabolism of drugs and lipids[J]. Acta Pharmaceutica Sinica B, 2016,6(5): 393-408